Talphera, Inc. TLPH

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
13/100
Weak

About Talphera, Inc.

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulation for direct IV infusion as an … Full TLPH analysis →

Competitive advantage assessment

Key strengths

  • Strong Liquidity Buffer Liquidity position is strong (score 0.90), providing operational cushion.

Key risks

  • Commodity Pressure / Weak Differentiation Gross margin at 1.2th percentile with high volatility suggests weak pricing power or commoditized products.
  • ROIC Below WACC or Peers ROIC at 13.4th percentile suggests inefficient capital deployment.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
2

Where TLPH ranks in Drug Manufacturers - Specialty & Generic

Talphera, Inc. ranks #80 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score — the top 88%. The widest moat in the group is Zoetis Inc. (ZTS) at 85/100.

Moat scores for companies ranked near TLPH in Drug Manufacturers - Specialty & Generic
# Company Moat score Rating
76 InMed Pharmaceuticals Inc. INM 19/100 Weak
77 Quantum Biopharma Ltd. QNTM 17/100 Weak
78 Incannex Healthcare Inc. IXHL 16/100 Weak
79 Akanda Corp. AKAN 13/100 Weak
80 Talphera, Inc. TLPH 13/100 Weak
81 Redhill Biopharma Ltd. RDHL 12/100 Weak
82 PainReform Ltd. PRFX 9/100 Weak
83 Shuttle Pharmaceuticals Holding SHPH 6/100 Weak
84 Bright Green Corporation BGXX 5/100 Weak

See every Pharma / Mature Biotech company ranked by moat score →

How TLPH scores on the Corporate Default defenses

Pricing Power

Score 2 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 3 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 10 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 8 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 49 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 2 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding TLPH's moat

What is Talphera, Inc.'s moat score?

Talphera, Inc. (TLPH) scores 13 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as weak. It ranks #80 of 91 scored companies in Drug Manufacturers - Specialty & Generic, the top 88%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 90 companies in Drug Manufacturers - Specialty & Generic. Its strongest defense is Resilience (49/100) and its weakest is Pricing Power (2/100).

How does Talphera, Inc. compare with other Drug Manufacturers - Specialty & Generic companies?

Talphera, Inc. ranks #80 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score. The widest moat in Drug Manufacturers - Specialty & Generic is Zoetis Inc. (ZTS) at 85/100. The companies ranked closest are Akanda Corp. (AKAN) at 13 just above it and Redhill Biopharma Ltd. (RDHL) at 12 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 90 companies in Drug Manufacturers - Specialty & Generic. The defenses are then weighted to produce the overall score out of 100.

Why is Talphera, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Talphera, Inc.?

The Corporate Default template measures 6 defenses, and TLPH scores: Pricing Power (2), Cost Advantage (3), Customer Stickiness (10), Capital Efficiency (8), Resilience (49), Scale & Market Position (2). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000